Amgen Inc. vs Kia Corporation: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Kia Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Kia Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Kia Corporation is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against ~$81B for Kia Corporation, while their respective market capitalizations stand at $228.2B and $32.4B. Amgen Inc. is headquartered in United States and Kia Corporation in South Korea, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Kia Corporation: Kia Corporation (KRX: 000270), headquartered at 12 Heolleung-ro, Seocho-gu, Seoul, is the second automaker in Hyundai Motor Group. It has been listed since July 1973. Hyundai Motor Company holds 35.17% of its shares, and Hyundai and its related parties hold 36.99% together. Foreign investors own 40.32% and Korea's National Pension Service owns 7.25% (end of 2025). Kia designs and markets its vehicles separately from Hyundai, but the two share engineering, platforms and suppliers. In 2025 it sold 3,135,873 vehicles, its best year so far. The best sellers were the Sportage, Seltos, Sorento and Carnival, along with a growing range of hybrid and EV models.

Amgen Inc. and Kia Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Kia Corporation.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

Kia Corporation business model: Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers. SUVs and RVs such as the Sportage, Sorento, Seltos, Carnival and Telluride make up most of the mix and earn more per unit than small sedans. Parts, accessories, service and connected-car subscriptions (Kia Connect) bring in further revenue from cars already on the road. Kia shares platforms, powertrains, the 800-volt E-GMP EV architecture and many suppliers with Hyundai Motor, which spreads engineering costs across both brands. Hyundai Mobis and Hyundai WIA are its biggest related-party suppliers: Kia's 2025 transactions with them were about $6.67 billion (KRW 9.4 trillion) and ~$2.63 billion (KRW 3.7 trillion). Hyundai Capital provides much of the retail and dealer financing. A newer line of business is purpose-built vehicles (PBVs), starting with the PV5 electric van, which are sold to businesses for delivery, ride-hailing and fleet use.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Kia Corporation.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Kia Corporation competitive advantage: Kia's main advantages are its scale inside Hyundai Motor Group and the way it can switch powertrains easily. Sharing platforms, the E-GMP 800V EV architecture, batteries, chips and logistics (Hyundai Glovis) with Hyundai lowers development and purchasing costs. Factories in Korea, the US (Georgia), Mexico, Slovakia and India let Kia shift production between combustion, hybrid and electric models. In the US, the 10-year/100,000-mile powertrain warranty and award-winning models (EV6, EV9, Telluride) have built buyer trust that its 1990s cars never had.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Kia Corporation each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

Kia Corporation growth strategy: Kia's current strategy, set out at the 2026 CEO Investor Day, uses several powertrains instead of only EVs. It plans to grow EVs (EV3, EV4, EV5, EV6, EV9 and later models) and hybrids together, add a PBV line of modular electric vans starting with the PV5, and build up software-defined vehicles, autonomous driving and robotics as longer-term businesses. By 2030 it is targeting 1.02 million sales in the US and 746,000 in Europe, along with growth in India and other emerging markets.

A closer look at the financial trajectory of Amgen Inc. and Kia Corporation rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

Kia Corporation: Kia's revenue has risen every year since 2020: from ~$49.6 billion (KRW 69.9 trillion) in 2021 to ~$76.3 billion (KRW 107.4 trillion) in 2024 and a record ~$81 billion (KRW 114.1 trillion) in 2025 (+6.2%). Profit has not kept up. Operating profit fell 28.3% in 2025 to ~$6.45 billion (KRW 9.08 trillion), and the margin dropped from 11.8% to 8.0% as US tariffs and incentives ate into earnings. Net profit was about $5.36 billion (KRW 7.55 trillion). The squeeze continued into 2026. Q1 revenue was a record ~$20.9 billion (KRW 29.50 trillion) (+5.3%), but operating profit fell 26.7% to ~$1.57 billion (KRW 2.21 trillion). Q2 revenue reached ~$23.5 billion (KRW 33.04 trillion) (+12.6%) while operating profit fell 4.9% to ~$1.87 billion (KRW 2.63 trillion). The shares dropped about 13% on the day of the Q2 results. Shareholder returns are still high: the 2025 dividend was KRW 6,800 per share, a 35% consolidated payout ratio, and Kia has been cancelling treasury shares, cutting issued shares from 405.4 million in 2022 to 390.4 million at the end of 2025.